GSK’s Votrient gains US FDA nod as soft tissue sarcoma treatment
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline won the US FDA's blessing to market Votrient (pazopanib), an antivascular endothelial growth factor receptor, as a treatment for patients with advanced soft tissue sarcoma (STS) previously treated with chemotherapy.